Download MendeleyPotent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor.
Zheng, B., D'Andrea, S.V., Sun, L.Q., Wang, A.X., Chen, Y., Hrnciar, P., Friborg, J., Falk, P., Hernandez, D., Yu, F., Sheaffer, A.K., Knipe, J.O., Mosure, K., Rajamani, R., Good, A.C., Kish, K., Tredup, J., Klei, H.E., Paruchuri, M., Ng, A., Gao, Q., Rampulla, R.A., Mathur, A., Meanwell, N.A., McPhee, F., Scola, P.M.(2018) ACS Med Chem Lett 9: 143-148
- PubMed: 29456803
- DOI: https://doi.org/10.1021/acsmedchemlett.7b00503
- Primary Citation of Related Structures:
6BQJ, 6BQK - PubMed Abstract:
The design and synthesis of potent, tripeptidic acylsulfonamide inhibitors of HCV NS3 protease that contain a difluoromethyl cyclopropyl amino acid at P1 are described. A cocrystal structure of 18 with a NS3/4A protease complex suggests the presence of a H-bond between the polarized C-H of the CHF 2 moiety and the backbone carbonyl of Leu135 of the enzyme. Structure-activity relationship studies indicate that this H-bond enhances enzyme inhibitory potency by 13- and 17-fold compared to the CH 3 and CF 3 analogues, respectively, providing insight into the deployment of this unique amino acid.
Organizational Affiliation:
Discovery Synthesis, Research and Development, Bristol-Myers Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543, United States.
